Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
äŒæ¥ã³ãŒãRENB
äŒç€ŸåLunai Bioworks Inc
äžå Žæ¥Nov 18, 2014
æé«çµå¶è²¬ä»»è
ãCEOãWeinstein (David)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 18
æ¬ç€Ÿæåšå°2080 Century Park East, Suite 906
éœåžLOS ANGELES
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·90067
é»è©±çªå·14539179840
ãŠã§ããµã€ã
äŒæ¥ã³ãŒãRENB
äžå Žæ¥Nov 18, 2014
æé«çµå¶è²¬ä»»è
ãCEOãWeinstein (David)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã